DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets. Pipeline programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer. Experienced team of individuals with expertise…